Incyte Drops Planned Phase 3 MAESTRA-3 Ovarian Cancer Study of CDK2 Inhibitor
Incyte has decided not to go ahead with a planned late-stage ovarian cancer study of an experimental drug, the company said in an 8-K filed Friday.
The company said it will not proceed with the Phase 3 MAESTRA-3 study, which would have evaluated INCB123667, its selective CDK2 inhibitor, in combination with bevacizumab as first-line maintenance therapy for patients with ovarian cancer. The study had been expected to begin in the fourth quarter of 2026, according to the filing.
Why Incyte made the call
Incyte said the decision was "based on the prioritization of its clinical development portfolio." It was "not based on any safety or efficacy findings" from the INCB123667 clinical program, the company said in the 8-K.
Guidance unchanged
Incyte said it does not expect the decision to affect its financial guidance or its previously disclosed long-term outlook.
The filing does not say whether other studies of INCB123667 will continue or what will happen to resources that had been planned for MAESTRA-3.
Key points
- Study: Phase 3 MAESTRA-3, INCB123667 plus bevacizumab, first-line maintenance in ovarian cancer
- Planned start: fourth quarter of 2026
- Reason given: clinical portfolio prioritization, not safety or efficacy findings
- Financial guidance: not expected to be affected
Sources
- Form 8-K, Incyte Corporation, filed Nov. 13, 2026, accession 0000879169-26-000068
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence. SI may make mistakes.